ALT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ALT is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has some speculative upside tied to pemvidutide and upcoming earnings, but the current technical setup is weak, analyst opinions are still mixed, and there is no strong proprietary buy signal. For an impatient investor who does not want to wait for a better entry, this is still not the right time to buy aggressively.
The short-term trend is weak. Price closed at 3.0109 after a 6.75% regular-session drop, and the moving averages are bearish with SMA_200 > SMA_20 > SMA_5, which points to a downtrend. MACD histogram is slightly positive and expanding, which is a mild improvement, but RSI_6 at 51.53 is neutral and does not confirm momentum. Key levels are pivot 2.901, resistance 3.168, and support 2.633. Overall, the chart shows a fragile bounce inside a broader bearish structure rather than a clean buy setup.
Upcoming Q1 2026 earnings on 2026-05-13 is the most immediate catalyst. The company continues to advance pemvidutide in MASH, alcohol use disorder, and alcohol-associated liver disease, which keeps the long-term story alive. Recent analyst updates have been constructive overall on the science and pipeline, with multiple Buy ratings and meaningful upside targets from some firms. Balance sheet improvement is also a positive, with Goldman noting pro forma cash near $400M, reducing near-term financing pressure.
The stock just sold off sharply on the day, and the broader trend remains bearish. Goldman Sachs recently only upgraded it to Neutral with a $2.50 target, which is below the current price, signaling limited near-term upside from at least one major house. The key Phase 3 pemvidutide data is not expected until 2029, which pushes major value realization far out. The stock trend model also points to negative expected performance over the next week and month. There are no recent congress trades or notable insider/politician buying signals to support the name.
Latest reported quarter is 2025/Q4. Revenue rose sharply to 26,000, up 420% YoY, which is a strong growth signal, but the company is still loss-making with net income of -27.36M and EPS of -0.26. Gross margin was 100, which is typical for a development-stage biotech with limited revenue. The main takeaway is improving top-line activity, but profitability is still distant.
Analyst sentiment has improved recently, but it is still mixed. Truist initiated Buy at $12, H.C. Wainwright raised its target to $25 and kept Buy, B. Riley kept Buy with a $13 target, and Titan initiated Buy at $7. On the weaker side, Goldman Sachs upgraded only to Neutral with a $2.50 target, reflecting a more cautious stance. Overall, Wall Street pros are split: bulls like the pipeline optionality and cash runway, while bears focus on delayed Phase 3 readout timing and execution risk.
